An adaptive Bayesian randomized controlled trial of traditional Chinese medicine in progressive pulmonary fibrosis: Rationale and study design.
10.1016/j.joim.2025.01.003
- Author:
Cheng ZHANG
1
;
Yi-Sen NIE
2
;
Chuan-Tao ZHANG
2
;
Hong-Jing YANG
2
;
Hao-Ran ZHANG
3
;
Wei XIAO
2
;
Guang-Fu CUI
2
;
Jia LI
2
;
Shuang-Jing LI
1
;
Qing-Song HUANG
4
,
5
;
Shi-Yan YAN
6
Author Information
1. School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
2. Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
3. College of Preschool Education, Beijing Youth Politics College, Beijing 100102, China.
4. Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China. Electronic address: huangqingsong5802@
5. com.
6. School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China; International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing 100029, China. Electronic address: yanshiyan@bucm.edu.cn.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
Adaptive trial design;
Bayesian model;
Progressive pulmonary fibrosis;
Traditional Chinese medicine
- MeSH:
Female;
Humans;
Male;
Bayes Theorem;
Disease Progression;
Drugs, Chinese Herbal/therapeutic use*;
Medicine, Chinese Traditional/methods*;
Pulmonary Fibrosis/therapy*;
Quality of Life;
Randomized Controlled Trials as Topic;
Research Design;
Adaptive Clinical Trials as Topic
- From:
Journal of Integrative Medicine
2025;23(2):138-144
- CountryChina
- Language:English
-
Abstract:
Progressive pulmonary fibrosis (PPF) is a progressive and lethal condition with few effective treatment options. Improvements in quality of life for patients with PPF remain limited even while receiving treatment with approved antifibrotic drugs. Traditional Chinese medicine (TCM) has the potential to improve cough, dyspnea and fatigue symptoms of patients with PPF. TCM treatments are typically diverse and individualized, requiring urgent development of efficient and precise design strategies to identify effective treatment options. We designed an innovative Bayesian adaptive two-stage trial, hoping to provide new ideas for the rapid evaluation of the effectiveness of TCM in PPF. An open-label, two-stage, adaptive Bayesian randomized controlled trial will be conducted in China. Based on Bayesian methods, the trial will employ response-adaptive randomization to allocate patients to study groups based on data collected over the course of the trial. The adaptive Bayesian trial design will employ a Bayesian hierarchical model with "stopping" and "continuation" criteria once a predetermined posterior probability of superiority or futility and a decision threshold are reached. The trial can be implemented more efficiently by sharing the master protocol and organizational management mechanisms of the sub-trial we have implemented. The primary patient-reported outcome is a change in the Leicester Cough Questionnaire score, reflecting an improvement in cough-specific quality of life. The adaptive Bayesian trial design may be a promising method to facilitate the rapid clinical evaluation of TCM effectiveness for PPF, and will provide an example for how to evaluate TCM effectiveness in rare and refractory diseases. However, due to the complexity of the trial implementation, sufficient simulation analysis by professional statistical analysts is required to construct a Bayesian response-adaptive randomization procedure for timely response. Moreover, detailed standard operating procedures need to be developed to ensure the feasibility of the trial implementation. Please cite this article as: Zhang C, Nie YS, Zhang CT, Yang HJ, Zhang HR, Xiao W, Cui GF, Li J, Li SJ, Huang QS, Yan SY. An adaptive Bayesian randomized controlled trial of traditional Chinese medicine in progressive pulmonary fibrosis: Rationale and study design. J Integr Med. 2025; 23(2): 138-145.
